Supplemental tables: Clinical manifestations and healthcare utilization before diagnosis of transthyretin amyloidosis

<p dir="ltr"><b>These are peer-reviewed supplementary materials for the article '</b><b>Clinical manifestations and healthcare </b><b>utilization before diagnosis of </b><b>transthyretin amyloidosis' published in the</b><b> </b><b><i>Journal of Comparative Effectiveness Research</i></b><b>.</b></p><ul><li><b>Supplemental Table I:</b> Diagnostic testing and therapeutic procedures during three years prior to diagnosis</li><li><b>Supplemental Table II: </b>Healthcare utilization during three years prior to diagnosis</li></ul><p dir="ltr"><b>Introduction:</b> Initial clinical manifestations of transthyretin amyloidosis (ATTR) are not well understood, making timely diagnosis challenging. <b>Methods:</b> Patients aged ≥68 years newly diagnosed with ATTR were identified using Medicare Research Identifiable Files. Symptom manifestation and healthcare utilization were measured during 3 years pre-diagnosis; demographics and comorbidity index during 1-year prediagnosis. Controls (ATTR-free) werematched 1:1 to patientswith ATTR based on age, sex and region; same index date and enrollment as match. <b>Results:</b> We identified 552 matched ATTR-control pairs: mean age 78.3 (standard deviation 6.3) and 64.5% male. Among patients with ATTR (vs controls), cardiovascular conditions (92.9 vs 75.9%) and hospitalization (54.0 vs 35.5%) were frequent during 3 years pre-diagnosis. <b>Conclusion:</b> Patients with ATTR have multiple symptoms and hospitalizations pre-diagnosis, recognition of which may facilitate earlier diagnosis and treatment.</p>